shows the evolution of the number of daily flushing episodes and bowel movements within the first month of lanreotide treatment, as well as of the intensity of symptoms. A significant decrease in the number offlushing episodes was seen after seven (p<005), 15 (p<005), and 30 days of treatment (p<0 05). Diarrhoea also decreased significantly (p<0-01 at day 7, day 15, and day 30), although complete resolution occurred less often than flushing (Table II) .
The intensity of both symptoms significantly decreased at all treatment intervals (p<0-001). The number and intensity of flushing episodes and bowel movements did not significantly differ in patients previously treated with octreotide, compared with those who had never been treated with this somatostatin analogue (p> 0. 1). Finally, lanreotide was completely ineffective for carcinoid symptoms in four patients (two with flushing, two with flushing and diarrhoea) who stopped treatment at the end of the first month. One patient resigned at day 7 for personal reasons; one patient died after one month because of a significant increase in liver metastases. Thirty three patients entered the longterm study. Table III shows the evolution of urinary 5 HIAA concentrations within the first month of treatment.
Biological markers

LONGTERM RESULTS
Drop outs
Nine of 33 patients stopped treatment before the end of the six month period. Two patients died after three months (one from peritoneal carcinomatosis, one from an unrelated cause). Carcinoid syndrome worsened in three patients, who left the study at the end of the third month; tumoral progression and surgical resection of the tumour occurred in one patient each. Finally, two patients left the study for personal reasons.
Symptoms
Patients' weight did not increase significantly (66.2 (17.7) kg at six months, v 64.6 (15.7) kg at inclusion). Figure 1 shows the actuarial proportions of patients without symptomatic improvement (defined as at least a 50% reduction in the number of flushing episodes and bowel movements) throughout the six month treatment period. A decrease of at least 50% was seen in 53 and 59% of the patients at six months, respectively. The mean (SD) number of flushing episodes decreased from 4.5 (0.7) before treatment to 1.6 (2.9) at LVCF (p=001). The mean (SD) number of daily bowel movements decreased from 4-8 (3.3) before treatment to 3.2 (2.0) at LVCF (p=0.01). A decrease of at least one degree in the intensity of symptoms was seen in 54 and 56% of the patients for flushing and diarrhoea, respectively (Fig 2) . Flushing episodes completely resolved in 12 of 31 (39%), 10 
Tolerability
Pain or erythema at the injection site was reported at least once by 25% of the patients. These symptoms tended to disappear after two or three injections, and were judged as 'mild' or 'moderate' in all cases. Four patients reported colic pain or abdominal bloating; transient fever was observed in two patients. A paradoxical increase in diarrhoea for one to three days after the lanreotide injection was seen in three patients. Small bowel obstruction due to peritoneal adhesion led to laparotomy in one patient who had been treated for one month.
Serum glucose values tended to be slightly higher after six months of lanreotide (5- 150 ,ug each, resulted in prompt and significant relief from both flushing and diarrhoea.12 Seventy nine and 76%, respectively of the patients had complete or significant relief from these symptoms at some time in the treatment (best response).
In this study conducted with 30 mg intramuscular of lanreotide, every other week, the number and intensity of flushing episodes decreased significantly within seven days and complete resolution was observed in 40% of the patients during the first month. These figures were maintained throughout the study as indicated by results showing 53% of the patients with at least a 50% decrease in the number of flushing episodes at six months. There are several possible reasons for this rate being slightly lower than those previously reported in studies with octreotide.5 1112
Firstly, a transient decrease in flushing was not defined as a response in our study if subsequent relapse occurred. Moreover, our study protocol did not permit an increase in lanreotide dose during the six month period. Tachyphylaxia has been shown to occur in many patients receiving octreotide, and was even noted in 35 of 51 patients (70%) treated by Janson and Oberg.1 In our study, some of the patients in whom lanreotide became ineffective and considered as treatment failures might have been controlled by increasing doses of this substance. Although significant, the effect of lanreotide on diarrhoea was less pronounced, at least on the number of daily bowel movements. Complete resolution was less often obtained than for flushing at the beginning of treatment, as previously noted with octreotide by others.5 However, the intensity of this symptom decreased very significantly and discomfort was mild during longterm treatment.
The effect of somatostatin analogues on biological markers varies quite widely in the carcinoid syndrome.1 5 
